Immunoglobulin isotype knowledge and application to Fc engineering

Current Opinion in Immunology

Volumn 40, Issue , 2016, Pages 62-69

  Brezski, Randall J ^a   Georgiou, George ^b,c  

^a GENENTECH INC   (United States)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; BISPECIFIC ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY;

AMINO ACID SUBSTITUTION; ANTIBODY ENGINEERING; HINGE REGION; IMMUNOGLOBULIN STRUCTURE; PROTEIN ENGINEERING; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOTHERAPY; PHAGOCYTOSIS; PROCEDURES; TRENDS;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN ISOTYPES; IMMUNOTHERAPY; PHAGOCYTOSIS;

EID: 84961192479     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.03.002     Document Type: Review

References (62)

1. Ecker D.M., Jones S.D., Levine H.L. The therapeutic monoclonal antibody market. MAbs 2015, 7:9-14.
2. Mossner E., Brunker P., Moser S., Puntener U., Schmidt C., Herter S., Grau R., Gerdes C., Nopora A., van Puijenbroek E., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115:4393-4402.
3. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
4. Furness A.J., Vargas F.A., Peggs K.S., Quezada S.A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014, 35:290-298.
5. Muller R., Grawert M.A., Kern T., Madl T., Peschek J., Sattler M., Groll M., Buchner J. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation. Proc Natl Acad Sci U S A 2013, 110:10183-10188.
6. Johansen F.E., Braathen R., Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol 2000, 52:240-248.
7. Collins C., Tsui F.W., Shulman M.J. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol 2002, 32:1802-1810.
8. Marks L. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin. MAbs 2012, 4:403-412.
9. Sun Z., Almogren A., Furtado P.B., Chowdhury B., Kerr M.A., Perkins S.J. Semi-extended solution structure of human myeloma immunoglobulin D determined by constrained X-ray scattering. J Mol Biol 2005, 353:155-173.
10. Ubelhart R., Hug E., Bach M.P., Wossning T., Duhren-von Minden M., Horn A.H., Tsiantoulas D., Kometani K., Kurosaki T., Binder C.J., et al. Responsiveness of B cells is regulated by the hinge region of IgD. Nat Immunol 2015, 16:534-543.
11. Strohl W.R. Isotype selection and Fc engineering: design and construction of fit-for-purpose therapeutic antibodies. Antibody drug discovery 2011, Imperial College Press, London.
12. Josephs D.H., Bax H.J., Lentfer H., Selkirk C., Spicer J.F., Karagiannis S.N. Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis. Lancet 2015, 385(Suppl 1):S53.
13. Rudman S.M., Josephs D.H., Cambrook H., Karagiannis P., Gilbert A.E., Dodev T., Hunt J., Koers A., Montes A., Taams L., et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy 2011, 41:1400-1413.
14. Boross P., Lohse S., Nederend M., Jansen J.H., van Tetering G., Dechant M., Peipp M., Royle L., Liew L.P., Boon L., et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013, 5:1213-1226.
15. Lohse S., Meyer S., Meulenbroek L.A., Jansen J.H., Nederend M., Kretschmer A., Klausz K., Moginger U., Derer S., Rosner T., et al. An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Res 2015.
16. Pincetic A., Bournazos S., DiLillo D.J., Maamary J., Wang T.T., Dahan R., Fiebiger B.M., Ravetch J.V. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 2014, 15:707-716.
17. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
18. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., Rossen K., van Berkel P.H., Derer S., Beyer T., Lohse S., Bleeker W.K., Peipp M., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010, 184:512-520.
19. Kinder M., Greenplate A.R., Strohl W.R., Jordan R.E., Brezski R.J. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs 2015, 7:494-504.
20. Dillon T.M., Ricci M.S., Vezina C., Flynn G.C., Liu Y.D., Rehder D.S., Plant M., Henkle B., Li Y., Deechongkit S., et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008, 283:16206-16215.
21. White A.L., Chan H.T., French R.R., Willoughby J., Mockridge C.I., Roghanian A., Penfold C.A., Booth S.G., Dodhy A., Polak M.E., et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015, 27:138-148.
22. Brezski R.J., Oberholtzer A., Strake B., Jordan R.E. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. MAbs 2011, 3:558-567.
23. Liu H., May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 2012, 4:17-23.
24. Stapleton N.M., Andersen J.T., Stemerding A.M., Bjarnarson S.P., Verheul R.C., Gerritsen J., Zhao Y., Kleijer M., Sandlie I., de Haas M., et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011, 2:599.
25. Brezski R.J., Kinder M., Grugan K.D., Soring K.L., Carton J., Greenplate A.R., Petley T., Capaldi D., Brosnan K., Emmell E., et al. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs 2014, 6:1265-1273.
26. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
27. Rispens T., Davies A.M., Ooijevaar-de Heer P., Absalah S., Bende O., Sutton B.J., Vidarsson G., Aalberse R.C. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem 2014, 289:6098-6109.
28. Labrijn A.F., Rispens T., Meesters J., Rose R.J., den Bleker T.H., Loverix S., van den Bremer E.T., Neijssen J., Vink T., Lasters I., et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol 2011, 187:3238-3246.
29. Labrijn A.F., Buijsse A.O., van den Bremer E.T., Verwilligen A.Y., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009, 27:767-771.
30. Borrok M.J., Luheshi N.M., Beyaz N., Davies G.C., Legg J.W., Wu H., Dall'Acqua W.F., Tsui P. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcalphaRI (CD89) binding. MAbs 2015, 7:743-751.
31. Kelton W., Mehta N., Charab W., Lee J., Lee C.H., Kojima T., Kang T.H., Georgiou G. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem Biol 2014, 21:1603-1609.
32. Davis J.H., Aperlo C., Li Y., Kurosawa E., Lan Y., Lo K.M., Huston J.S. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010, 23:195-202.
33. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7:622-632.
34. Alegre M.L., Collins A.M., Pulito V.L., Brosius R.A., Olson W.C., Zivin R.A., Knowles R., Thistlethwaite J.R., Jolliffe L.K., Bluestone J.A. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 1992, 148:3461-3468.
35. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
36. An Z., Forrest G., Moore R., Cukan M., Haytko P., Huang L., Vitelli S., Zhao J.Z., Lu P., Hua J., et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009, 1:572-579.
37. Vafa O., Gilliland G.L., Brezski R.J., Strake B., Wilkinson T., Lacy E.R., Scallon B., Teplyakov A., Malia T.J., Strohl W.R. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2014, 65:114-126.
38. Natsume A., In M., Takamura H., Nakagawa T., Shimizu Y., Kitajima K., Wakitani M., Ohta S., Satoh M., Shitara K., et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008, 68:3863-3872.
39. Brezski R.J., Vafa O., Petrone D., Tam S.H., Powers G., Ryan M.H., Luongo J.L., Oberholtzer A., Knight D.M., Jordan R.E. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 2009, 106:17864-17869.
40. Fan X., Brezski R.J., Fa M., Deng H., Oberholtzer A., Gonzalez A., Dubinsky W.P., Strohl W.R., Jordan R.E., Zhang N., et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 2012, 14:R116.
41. Zhang N., Deng H., Fan X., Gonzalez A., Zhang S., Brezski R.J., Choi B.K., Rycyzyn M., Strohl W., Jordan R., et al. Dysfunctional antibodies in the tumor microenvironment associate with impaired anticancer immunity. Clin Cancer Res 2015.
42. Biancheri P., Brezski R.J., Di Sabatino A., Greenplate A.R., Soring K.L., Corazza G.R., Kok K.B., Rovedatti L., Vossenkamper A., Ahmad N., et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 2015.
43. Kinder M., Greenplate A.R., Grugan K.D., Soring K.L., Heeringa K.A., McCarthy S.G., Bannish G., Perpetua M., Lynch F., Jordan R.E., et al. Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem 2013, 288:30843-30854.
44. Srivastava R.M., Lee S.C., Andrade Filho P.A., Lord C.A., Jie H.B., Davidson H.C., Lopez-Albaitero A., Gibson S.P., Gooding W.E., Ferrone S., et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013, 19:1858-1872.
45. Eissler N., Ruf P., Mysliwietz J., Lindhofer H., Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 2012, 72:3958-3966.
46. Hess J., Ruf P., Lindhofer H. Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 2012, 8:73-85.
47. Labrijn A.F., Meesters J.I., de Goeij B.E., van den Bremer E.T., Neijssen J., van Kampen M.D., Strumane K., Verploegen S., Kundu A., Gramer M.J., et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013, 110:5145-5150.
48. Warncke M., Calzascia T., Coulot M., Balke N., Touil R., Kolbinger F., Heusser C. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol 2012, 188:4405-4411.
49. Davies A.M., Jefferis R., Sutton B.J. Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol 2014, 62:46-53.
50. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.
51. Diebolder C.A., Beurskens F.J., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
52. de Jong R.N., Beurskens F.J., Verploegen S., Strumane K., van Kampen M.D., Voorhorst M., Horstman W., Engelberts P.J., Oostindie S.C., Wang G., et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol 2016, 14:e1002344.
53. Ball C., Fox B., Hufton S., Sharp G., Poole S., Stebbings R., Eastwood D., Findlay L., Parren P.W., Thorpe R., et al. Antibody C region influences TGN1412-like functional activity in vitro. J Immunol 2012, 189:5831-5840.
54. Roux K.H., Strelets L., Michaelsen T.E. Flexibility of human IgG subclasses. J Immunol 1997, 159:3372-3382.
55. Tian X., Vestergaard B., Thorolfsson M., Yang Z., Rasmussen H.B., Langkilde A.E. In-depth analysis of subclass-specific conformational preferences of IgG antibodies. IUCrJ 2015, 2:9-18.
56. Senior B.W., Woof J.M. The influences of hinge length and composition on the susceptibility of human IgA to cleavage by diverse bacterial IgA1 proteases. J Immunol 2005, 174:7792-7799.
57. Oganesyan V., Damschroder M.M., Cook K.E., Li Q., Gao C., Wu H., Dall'Acqua W.F. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem 2014, 289:7812-7824.
58. Kiyoshi M., Caaveiro J.M., Kawai T., Tashiro S., Ide T., Asaoka Y., Hatayama K., Tsumoto K. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun 2015, 6:6866.
59. Ramsland P.A., Farrugia W., Bradford T.M., Sardjono C.T., Esparon S., Trist H.M., Powell M.S., Tan P.S., Cendron A.C., Wines B.D., et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011, 187:3208-3217.
60. Mimoto F., Katada H., Kadono S., Igawa T., Kuramochi T., Muraoka M., Wada Y., Haraya K., Miyazaki T., Hattori K. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). Protein Eng Des Sel 2013, 26:589-598.
61. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000, 406:267-273.
62. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000, 164:4178-4184.